Last updated: February 27, 2026
What is the drug associated with NDC 70000-0397?
NDC 70000-0397 corresponds to Alectinib (brand name Alecensa), a kinase inhibitor used for treating ALK-positive non-small cell lung cancer (NSCLC). Alectinib is approved for both metastatic and locally advanced cases.
Current Market Landscape
Market Size and Demand
- Prevalence: ALK-positive NSCLC accounts for approximately 3-5% of all NSCLC cases.
- Incidence: Estimated at 15,000-20,000 new cases annually in the United States.
- Treatment longevity: Patients typically remain on therapy for 1-2 years, impacting replenishment cycles.
Competition
- Key competitors: Crizotinib, Brigatinib, Lorlatinib.
- Market share (2022): Alectinib leads with ~50% among first-line ALK inhibitors, according to IQVIA data.
- Patent status: Patent exclusivity extends until 2026 in the U.S., with potential patent extensions pending.
Regulatory and Reimbursement Environment
- FDA approvals: Initial approval in 2015; expanded indications in subsequent years.
- Pricing: List price approximately $11,000 per month (as per manufacturer reports), with discounts and rebates affecting net payer cost.
- Reimbursement: Predominantly covered under Medicare and commercial insurance, with strong formulary inclusion due to efficacy.
Price Projections
Historical Price Trends
| Year |
Average Wholesale Price (AWP) |
Notes |
| 2015 |
~$10,500 |
Launch price; initial market entry |
| 2018 |
~$11,000 |
Slight increase, driven by inflation |
| 2020 |
~$11,000 |
Stable pricing; no major generic threat |
Future Price Trajectory (2023-2027)
- Patent expiration impact: Predicted entry of generics starting 2026 could lead to a 30-50% price reduction.
- Market dynamics: Patent litigation and exclusivity extensions can delay generics, maintaining high prices until 2026.
- Pricing forecast:
| Year |
Estimated Average Wholesale Price (AWP) |
Assumption |
| 2023 |
~$11,000 |
Stable, market-controlled price |
| 2024 |
~$11,000 |
No major pricing adjustments |
| 2025 |
~$10,500 |
Slight discounting for formulary negotiations |
| 2026 |
$6,000–$7,000 |
Initiation of generic competition |
| 2027 |
$3,000–$4,000 |
Increased generic market penetration |
Market Penetration & Pricing Factors
- Entry of biosimilars or generics typically cuts prices by 30-50%.
- Use of value-based pricing and managed entry agreements may moderate price declines.
- The high efficacy profile keeps some insurers negotiating for preferred formulary placement, possibly sustaining higher prices into 2025.
Revenue Projections
- 2023: Approximate U.S. sales of $1.3 billion (IQVIA 2022).
- 2024-2025: Maintain revenue levels with modest growth.
- 2026 onwards: Revenue declines by up to 70% depending on generic market uptake.
| Year |
Estimated U.S. Revenue |
Notes |
| 2023 |
~$1.3 billion |
Based on high market share among ALK inhibitors |
| 2024 |
~$1.2 billion |
Slight decline expected |
| 2025 |
~$900 million |
Market saturation; price pressure increases |
| 2026 |
~$300–$600 million |
Generic entry and increased competition |
Key Market Risks & Opportunities
-
Risks:
- Patent litigation delays generic entry.
- Patent expiry might prompt price erosion prior to generic launch due to biosimilars or substitutes.
- Competition from other ALK inhibitors with broader indications.
-
Opportunities:
- Expansion of indications (e.g., early-stage treatment).
- Enhanced biosimilar development could accelerate price decreases.
- Strategic partnerships for combination therapies.
Summary
Alectinib (NDC 70000-0397) commands a high market share in ALK-positive NSCLC treatment, maintaining prices around $11,000/month until patent expiration in 2026. Post-patent period likely sees a significant price decline due to generic competition, with revenues dropping considerably amid increased competition.
Key Takeaways
- The current market for Alectinib is ~$1.3 billion annually in the U.S., dominated by patent exclusivity until 2026.
- Price stabilization is expected until patent expiry; post-2026, prices may halve or more upon generic entry.
- Competition from other ALK inhibitors and potential biosimilar entrants influences pricing and market share.
- Patent litigation and regulatory policies can alter timelines and pricing projections.
- Ongoing clinical expansion offers opportunities beyond current indications.
FAQs
Q1: How long will live patents protect Alectinib from generics?
A1: Patent protection extends until 2026, with potential extensions based on patent litigation outcomes.
Q2: What is the expected price reduction after patent expiry?
A2: Prices may decline by 30–50%, with per-month costs dropping to approximately $6,000–$7,000.
Q3: Which competitors pose the greatest threat to Alectinib?
A3: Brigatinib (Alunbrig) and Lorlatinib (Lorbrena) are key competitors, with both expanding indications and market share.
Q4: How does market penetration impact future prices?
A4: Higher penetration accelerates price erosion, especially once generics enter the market.
Q5: What strategic actions can influence the pricing trajectory?
A5: Patent extension litigation, biosimilar development, and formulary negotiations can impact future prices.
References
[1] IQVIA (2022). Oncology Market Reports.
[2] FDA (2022). Label and Approval Documents for Alecensa.
[3] EvaluatePharma (2022). Oncology Drug Price and Sales Forecasts.
[4] Centers for Medicaid & Medicare Services (2022). Reimbursement Policies.
